Price
Target price
€10.36
€10.36
-10.020%
-1.14
-10.020%
€24.90
16.07.26 / Tradegate
WKN: A2AG6H / Symbol: NTLA / Name: Intellia / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Intellia Therapeutics Inc Stock
Heavy losses for Intellia Therapeutics Inc today as the stock fell by -€1.140 (-10.020%).
Currently there is a rather positive sentiment for Intellia Therapeutics Inc with 26 Buy predictions and 5 Sell predictions.
With a target price of 24 € there is potential for a 131.66% increase which would mean more than doubling the current price of 10.36 € for Intellia Therapeutics Inc.
Our community identified positive and negative aspects for Intellia Therapeutics Inc stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Intellia Therapeutics Inc stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Intellia Therapeutics Inc in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Cons
?
B****
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Intellia Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | -10.020% | -23.373% | -17.516% | 0.729% | 32.718% | -73.551% | -90.948% |
| Chromadex Corp | -1.990% | -2.632% | 1.370% | -69.485% | -46.182% | 104.138% | -61.307% |
| Cardio3 Biosciences S.A. | -1.430% | 7.254% | -7.589% | -32.792% | 53.333% | -59.728% | -94.185% |
| Polynovo Ltd | 2.630% | 0.000% | 5.405% | -7.143% | -13.971% | -38.095% | -54.297% |
Comments
Intellia Therapeutics (NTLA) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $49.00 price target on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NTLA) had its "buy" rating reaffirmed by HC Wainwright. They now have a $25.00 price target on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NTLA) had its price target lowered by HC Wainwright from $30.00 to $25.00. They now have a "buy" rating on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
News
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
An exciting new CRISPR-based tool is making waves in the scientific literature this spring. Because the new technology destroys targeted diseased cells outright rather than editing their genetic
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%
Intellia Therapeutics (NASDAQ: NTLA) has been on fire this year. Shares of the clinical-stage biotech have climbed an impressive 83% to date. However, Wall Street remains bullish on the company
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
Choosing between Intellia Therapeutics (NASDAQ:NTLA) and Omeros (NASDAQ:OMER) in 2026 requires balancing the explosive potential of gene editing against the steady rollout of newly approved orphan